Megablockbuster day for Roche too as MS game-changer Ocrevus gets a green light at the FDA
Tuesday turned out to be the day for a game of megablockbusters. Regeneron and Sanofi snagged an FDA OK for Dupixent, a landmark …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
